Lesson plan
NIBR2130
NIBR2130, also known as 6-(phenylcarbamoyl)-6-nor-LSD, is a small-molecule chemokine CXCR3 receptor antagonist which has been used in scientific research. It is a lysergamide and is a derivative of the psychedelic drug lysergic acid diethylamide (LSD). In contrast to LSD, NIBR2130 shows profoundly reduced affinities for monoamine receptors ( = 750–>10,000 nM). Instead, it was surprisingly found to act as a selective and highly potent chemokine CXCR3 receptor antagonist, with an affinity ( ) of 54 nM and an inhibitory potency ( ) of 18 to 74 nM. Unlike NIBR2130, LSD itself is completely inactive at the chemokine CXCR3 receptor. NIBR2130 can fully block the chemokine CXCR3 receptor in rodents in vivo. Various analogues of NIBR2130 have also been studied and described, with some of them substantially more potent as chemokine CXCR3 receptor antagonists and some of them acting as highly potent histamine H 3 receptor antagonists with potential applications in treatment of narcolepsy. NIBR2130 was first described in the scientific literature by 2008.
Article summary
NIBR2130, also known as 6-(phenylcarbamoyl)-6-nor-LSD, is a small-molecule chemokine CXCR3 receptor antagonist which has been used in scientific research. It is a lysergamide and is a derivative of the psychedelic drug lysergic acid diethylamide (LSD). In contrast to LSD, NIBR2130 shows profoundly reduced affinities for monoamine receptors ( = 750–>10,000 nM). Instead, it was surprisingly found to act as a selective and highly potent chemokine CXCR3 receptor antagonist, with an affinity ( ) of 54 nM and an inhibitory potency ( ) of 18 to 74 nM. Unlike NIBR2130, LSD itself is completely inactive at the chemokine CXCR3 receptor. NIBR2130 can fully block the chemokine CXCR3 receptor in rodents in vivo. Various analogues of NIBR2130 have also been studied and described, with some of them substantially more potent as chemokine CXCR3 receptor antagonists and some of them acting as highly potent histamine H 3 receptor antagonists with potential applications in treatment of narcolepsy. NIBR2130 was first described in the scientific literature by 2008.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.